Amrize AG heads into the final stretch of summer with a striking insider buying cluster — four executives purchasing shares in a three-day window — even as the stock extends its steepest monthly decline since the Holcim spin-off.
The insider signal is the clearest thing happening at Amrize right now. Four officers bought shares in open-market transactions between August 25 and August 27, none under a pre-arranged trading plan. Director Jacques Wolf Sanche spent roughly $187,000 picking up 4,150 shares at CHF 45.02. Chief Legal Officer Denise Singleton added 3,500 shares for $154,000, and Chief Marketing Officer Nollaig Forrest bought 1,500 shares at CHF 44.15. These are discretionary purchases — not compensation mechanics — made while the stock was already down more than 11% on the month. Net insider buying over the trailing 90 days totals roughly $408,000 across 9,155 shares, with no selling activity in the same window. The cluster echoes a larger buying episode from late October 2025, when Chairman and CEO Jan Philipp Jenisch purchased 110,000 shares for approximately $5.8 million across two sessions — a rare show of conviction that preceded the stock trading above CHF 50.
The price context makes the buying more pointed. Amrize closed at CHF 35.13 on September 1, down 1.2% on the day and roughly half a percent on the week. That puts the stock well below every insider purchase price visible in the recent data — the August buyers paid CHF 44–45, implying they are already underwater. The month's 11.5% decline stands out against a mixed peer tape. US aggregates names and each fell around 5% on the week, and dropped a similar amount. Former parent bucked the sector, rising just over 1% on the week — a divergence that underscores how much of Amrize's weakness reflects company-specific repositioning rather than a broad materials selloff.
The lending market offers no drama. Borrow availability is extraordinarily loose, running at roughly 2,482% — meaning there are nearly 25 shares available to lend for every one currently borrowed. That is well above the 52-week low availability reading of 378%, and the trend is moving further in that direction, with availability expanding 24% on the week. Cost to borrow is a negligible 0.61%, barely changed over the month. Short interest is not a meaningful factor here: the ORTEX short score has drifted down to 29.4 from 31.1 two weeks ago, and the lending market corroborates that bears are not building.
One item on the register worth noting: Thomas Schmidheiny filed a Schedule 13D in June 2025, disclosing a 6.67% activist stake. A 13D signals an intent to engage with management, not merely passive ownership, and Schmidheiny's institutional data shows his position unchanged as of the most recent report. As always with 13D/G disclosures, the stake is "as last disclosed" — positions can shift without a further filing once they drop below the 5% threshold.
Valuation has re-rated lower alongside the price. The price-to-book multiple has fallen 0.21x over the past 30 days to 1.69x, and the PE has compressed from roughly 17.2x to 15.5x. At that level, Amrize trades at a material discount to where its own executives have been buying. The next scheduled earnings event is October 26, and the historical record is stark: the August 7 print triggered a 9.8% one-day drop, and a closely related August 6 event produced a 10.4% decline extending to 11.5% over five days. With that kind of earnings volatility on record and insiders already buying ahead of the October release, the shape of the setup into that print is worth monitoring closely.
See the live data behind this article on ORTEX.
Open AMRZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
